Novartis Announced New Data From ALITHIOS Open-label Extension Study, Showing First-line Kesimpta (Ofatumumab) Treatment For Up To Six Years Led To Less Disability And Disease Progression In Recently Diagnosed And Treatment-naïve Relapsing Multiple...
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.